Latest Headlines in Biotech
Moderna seeks full FDA approval for its COVID-19 vaccine
If regulators grant the approval, it would follow the full clearance earlier this week of the vaccine made by Pfizer and BioNTech.
Another piece of Boston’s old industrial waterfront is poised to become . . . lab space
Here's a look at the proposals, which all involve putting up lab buildings that are seven or eight stories high.
Pfizer to acquire cancer drugmaker Trillium for $2.3 billion
Trillium’s two lead molecules block signaling proteins involved in blood cancers and are both in human trials across several types of disease.
Medford RNA firm GreenLight Biosciences to go public in $1.2b deal
The company’s research includes pesticide alternatives and a COVID-19 vaccine candidate.
Moderna’s vaccine gets provisional OK in Australia
The Cambridge company says the first 10 million doses will start shipping next month.
Adagio raises $300 million in IPO, looks to advance COVID-19 antibody therapy
The company said it could seek emergency use approval from the FDA for its treatment in early 2022.
EQRx to go public in $1.8 billion SPAC deal, with plan to make drugs cost less
The Cambridge startup says some of its late-stage programs would address cancer and inflammatory conditions.
Moderna says its COVID vaccine remains effective after six months, but booster needed before winter
The Cambridge company’s vaccine remained 93 percent effective six months after people received the second shot, Moderna said Thursday, although the data was totaled before the emergence of the highly contagious Delta variant.